Additionally, combining ibrutinib with anti-CD19 CAR-T was a promising idea to treat heavily pretreated CLL individuals or untreated CLL patients with TP53 disruption. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.